All In Biotech

Drug Trial Radar · NCT07185243

A Study to Evaluate Combination Therapy of Oncolytic Vaccinia Virus (hV01) and PD-1 Inhibitor in Advanced Solid Tumors.

A Study Evaluating the Safety and Efficacy of hV01, a Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus, in Combination With the PD-1 Inhibitor Tislelizumab for Advanced Solid Tumors.

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Jun 23, 2025

Primary completion

Jun 2027

Study completion Jun 2028

Sponsor

Lead sponsor
Hangzhou Converd Co., Ltd.Industry
Sponsor type
Industry
Collaborators
Xiamen Humanity Hospital
First posted
Sep 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and primary efficacy of the combination therapy of recombinant human IL-21-expressing oncolytic vaccinia virus (hV01) and the PD-1 Inhibitor Tislelizumab in patients with advanced solid tumors.

Conditions

  • Advanced Solid Tumors

Interventions

  • recombinant human IL-21-expressing oncolytic vaccinia virus injectionBiological

    hV01 is a recombinant vaccinia virus with deletions of the viral thymidine kinase (TK) and viral growth factor (VGF) genes and insertion of the human IL-21 gene.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicitiesTime frame: From the first hV01 dose till the end of cycle 1 (each cycle is 28 days in Part A and 42 days in Part B of the study).
  2. Adverse eventsTime frame: From informed consent to approximately 3 months after the End of Treatment (EOT).

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Xiamen Humanity Hospital

    Xiamen, Fujian, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.